Clinical trial
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab +…
NCT02242942 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02242942 |
|---|---|
| Title | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia |
| Official title | A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | AbbVie Industry German CLL Study Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lymphocytic Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | Chlorambucil, Venetoclax, Obinutuzumab |
| Enrollment | 445 |
| Start date | Dec 31, 2014 |
| Primary completion | Aug 17, 2018 |
| Completion | Aug 27, 2025 |
| First posted | Sep 17, 2014 |
| Last update posted | Nov 6, 2025 |
| Countries | Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Croatia, Denmark, Estonia, France, Germany, Italy and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: